Bio-Rad Laboratories, Inc. (AMEX: BIO) and (AMEX: BIOb), a multinational manufacturer and distributor of life science research products and clinical diagnostics, announced today that it has reached a settlement agreement with bioMérieux resolving various licensing disputes between the two companies. The licensing disputes were originally between bioMérieux and Pasteur Sanofi Diagnostics (PSD) and were part of Bio-Rad’s acquisition of PSD in 1999. Additionally, bioMérieux has granted Bio-Rad a license under its Epstein-Barr virus patent rights. As a result of the settlement, Bio-Rad anticipates a one-time impact on its diagnostics revenue of an additional $10 to $12 million in the second quarter of 2006.
